A Dutch court Monday ordered Johnson & Johnson (J&J) to pay a Swiss biotech company $130 million for breaching its license agreement. J&J had entered into an agreement to run clinical trials for a drug developed by the company, but the drug was denied approval by the FDA after telling J&J it was not properly overseeing those trials. George Chressanthis, professor of health-care management at Temple, said the $130 million probably isn't fazing J&J, a $62 billion company, too much. "The fine is secondary to the reputational effect, and also what it says to regulators, physicians and patients about whether or not they have the right quality controls and are adhering to best practices."